Objective and hypotheses: To evaluate the long-term efficacy of triptorelin 3.75 mg subcutaneously injection every 6 weeks on final height in girls with ICPP.
Method: Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously injection and reached FAH were collected. These patients were divided into two groups. Group A: GnRHa alone, n=17; group B: triptorelin+rhGH, n=23. During the treatment, height, weight, annual GV, sexual development, PAH and adverse effects were observed. BA and height SDS were monitored yearly. After discontinuation of treatment, follow-up was continued for 49 years till final height was attained.
Results: FAHs were 159.81±4.95 and 161.01±4.89 cm respectively in the two groups, exceed the genetic target height (THt), about the 50th percentile of normal female height. FAH increased by 1.51±4.30 cm, 4.86±4.49 cm from THt respectively. The values of (FAHTHt) and (FAHPAH post-treatment) showed significant difference between the two groups (P<0.05). FAH was positively correlated with Ht SDS-BA at the end of treatment, THt, course of rhGH treatment and age of menarche (R2=0.66). BMI increased after treatment, however, compared with healthy children at the same age, there was no significant tendency of increase. Ages of menarche were 11.74±0.66 years and 12.18±0.69 years respectively. Times of menarche from discontinuation were 17.41±6.96 and 14.71±4.77 months respectively.
Conclusion: The FAH was improved effectively by GnRHa 3.75 mg subcutaneously injection every 6 weeks, and more height gain will be achieved when rhGH was used concomitantly to refrain from growth deceleration during the treatment. BMI maintained steadily and ovarian function restored quickly after discontinuation of the treatment with the age of menarche similar to that of normal children.
20 - 22 Sep 2014
European Society for Paediatric Endocrinology